The public offering includes 781,251 shares of its common stock for $2.56 per share, according to a March 4 news release.
The company said it plans to use proceeds from the offering to support clinical trials, its patent portfolio and general corporate purposes, as well as for working capital.
From product launches and milestones, here are five updates in orthobiologics since March 28. 1. Lenoss Medical’s OsteoPearl procedure reached…
CGBIO, a South Korea-based company, earned the FDA’s investigational device exemption approval for its Novosis putty for spinal fusions. The…
A study reporting on DiscGenics’ cell therapy phase 1 and 2 study has been selected as one of three of…
Comments are closed.